Compare NICM & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NICM | BNR |
|---|---|---|
| Founded | N/A | 2014 |
| Country | Canada | China |
| Employees | 25 | 667 |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.4M | 94.4M |
| IPO Year | N/A | 2019 |
| Metric | NICM | BNR |
|---|---|---|
| Price | $5.85 | $9.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.0K | ★ 15.0K |
| Earning Date | N/A | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.77 | $5.31 |
| 52 Week High | $6.48 | $41.72 |
| Indicator | NICM | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 47.97 | 42.06 |
| Support Level | $5.92 | $8.34 |
| Resistance Level | $6.38 | $10.00 |
| Average True Range (ATR) | 0.16 | 0.85 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 35.34 | 6.41 |
Nicola Mining Inc is a junior exploration and custom milling company that is engaged in the business of identification, acquisition, and exploration of mineral property interests, together with custom milling partnerships at its Merritt Mill. The company holds interests in various claims at the following properties: the Treasure Mountain Property, New Craigmont Property, and Dominion Creek Property. Its portfolio of producing assets and development projects is mainly composed of copper, gold, and silver properties spread across British Columbia, Canada.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.